last
sever
decad
impress
advanc
nucleic
acid
deliveri
brought
technolog
clinic
three
gene
therapi
approv
us
food
drug
administr
fda
reli
viral
deliveri
system
nonvir
system
less
immunogen
viral
system
may
requir
case
repeat
administr
necessari
nonmutagen
stabl
viral
integr
gene
may
benefici
treatment
genet
disord
transient
regul
gene
express
may
prefer
context
nonvir
nucleic
acid
deliveri
yet
reach
fda
approv
sever
nanoparticl
np
base
therapeut
current
clinic
trial
thorough
review
nonvir
nucleic
acid
therapi
clinic
develop
suggest
yin
et
al
deliveri
platform
reach
regulatori
approv
unit
state
elsewher
pave
way
nucleic
acid
therapeut
cancer
diseas
parallel
advanc
nucleic
acid
deliveri
develop
immunotherapi
revolution
cancer
treatment
although
histor
cancer
therapi
focus
directli
kill
cancer
cell
chemotherapi
radiat
success
immun
checkpoint
inhibitor
chimer
antigen
receptor
car
tcell
demonstr
turn
immun
tumor
microenviron
tme
cancer
strong
therapeut
effect
hoo
howev
immuneoncolog
drug
effect
subset
patient
suggest
addit
factor
play
immun
suppress
tme
one
critic
factor
hamper
tcell
invas
antitumor
effect
taken
togeth
har
npbase
nucleic
acid
deliveri
tme
could
transform
protumor
immunosuppress
tme
toxic
environ
cancer
cell
review
preclin
studi
demonstr
feasibl
nucleic
acid
deliveri
tme
cancer
therapi
lipid
system
vitro
gene
deliveri
first
develop
primarili
compos
amphiphil
cation
lipid
felgner
et
al
molecul
contain
polar
head
group
linker
fatti
acid
chain
selfassembl
micellar
lamellar
hexagon
structur
water
exampl
includ
n
propyl
n
n
ntrimethylammonium
chlorid
dotma
dotap
incorpor
cholesterol
neutral
lipid
dope
also
increas
stabil
transfect
effici
perman
charg
lipid
result
toxic
therefor
ioniz
system
develop
ioniz
lipid
posit
charg
mildli
acid
condit
complex
nucleic
acid
howev
remain
uncharg
neutral
ph
avoid
system
toxic
rietwyk
peer
polym
also
use
encapsul
nucleic
acid
vivo
deliveri
gener
polym
divid
two
group
natur
synthet
biolog
occur
molecul
peptid
oligosaccharid
even
nucleic
acid
natur
polym
synthet
polym
chemic
produc
poli
lacticcoglycol
acid
plga
polym
occur
singl
repeat
unit
homopolym
multipl
unit
type
copolym
addit
polym
discret
segment
consist
differ
repeat
unit
call
blockcopolym
made
varieti
use
properti
cation
polym
polyllysin
pll
polyethylenimin
pei
earliest
polym
use
condens
dna
pei
superior
transfect
effici
develop
vivo
clinic
deliveri
nucleic
acid
yin
et
al
combin
plga
safe
biodegrad
form
stabl
np
pei
mix
polym
np
allow
effect
gene
deliveri
vivo
bivasbenita
et
al
neutral
polym
polyethylen
glycol
peg
also
use
reduc
electrostat
interact
polym
lipidbas
np
vivo
storm
et
al
anoth
nucleic
acid
deliveri
agent
gain
popular
chitosan
natur
copolym
act
biodegrad
gene
deliveri
agent
wang
et
al
wide
varieti
materi
use
nanoformul
nucleic
acid
deliveri
combin
divers
materi
formul
techniqu
result
np
array
size
charg
surfac
properti
properti
np
use
nucleic
acid
deliveri
tme
preclin
studi
summar
tabl
case
solid
tumor
deliveri
cancer
cell
formid
hurdl
pecot
et
al
evid
toler
intracellular
deliveri
demonstr
phase
clinic
trial
lipid
polymer
np
zuckerman
davi
leaki
ineffici
vasculatur
allow
accumul
np
tumor
prabhakar
et
al
solid
tumor
also
stroma
contain
vast
milieu
noncancer
constitu
includ
fibroblast
tumorassoci
macrophag
tam
endotheli
cell
extracellular
matrix
compon
ecm
addit
impair
access
tumor
parenchyma
case
np
load
small
molecul
drug
deliveri
tam
tme
may
benefici
local
sustain
releas
drug
miller
et
al
case
nucleic
acid
deliveri
deliveri
appropri
cell
requir
payload
must
also
reach
key
intracellular
compart
strategi
allow
better
penetr
np
tumor
stroma
explor
caution
warrant
disrupt
tumor
stroma
may
remov
import
element
nutrit
growth
factor
also
promot
resist
miao
et
al
one
altern
strategi
target
tumorassoci
cell
within
tme
cancer
therapi
commonli
found
tumor
peripheri
cell
first
encount
np
leav
circul
mani
cell
type
within
tme
also
express
uniqu
cell
surfac
marker
util
target
deliveri
given
influenc
tme
cell
hallmark
cancer
entic
direct
pursu
hanahan
coussen
tme
cell
type
role
cancer
biolog
surfac
marker
commonli
use
target
summar
figur
deliveri
exogen
dna
offer
great
therapeut
opportun
cancer
one
approach
overexpress
gene
suppress
kill
tumor
cell
gene
human
origin
viral
protein
bacteri
toxin
protein
design
desir
function
one
exampl
np
deliveri
gene
encod
antitumor
viral
protein
success
deliv
express
human
chang
et
al
yoo
et
al
ueno
et
al
mani
barrier
gene
deliveri
univers
oligonucleotid
speci
stabil
circul
cell
uptak
endosom
escap
dna
must
addit
deliv
nuclear
compart
permit
access
transcript
machineri
shown
year
ago
dna
microinject
nucleu
cytosol
produc
gene
product
capecchi
improv
deliveri
system
alter
dna
sequenc
enhanc
nuclear
deliveri
exampl
import
nucleu
aid
inclus
nuclear
local
signal
nl
plasmid
dna
pdna
sequenc
et
al
zanta
et
al
also
strong
viral
eukaryot
promot
sequenc
ad
activ
transcript
capecchi
plasmid
tailor
use
tissuespecif
promot
reduc
potenti
offtarget
effect
gorski
et
al
import
safeti
concern
dna
deliveri
immun
stimul
risk
insert
mutagenesi
risk
insert
mutagenesi
much
higher
viral
deliveri
system
exclud
episom
pdna
glover
et
al
baum
et
al
like
oligonucleotid
dna
stimul
immun
respons
consid
design
therapeut
immun
respons
dna
caus
unmethyl
cpg
motif
stimul
bcell
prolifer
cytokin
releas
krieg
et
al
klinman
et
al
hemmi
et
al
robust
immunostimmulatori
effect
cpg
dna
make
potenti
use
vaccin
adjuv
gurunathan
et
al
altern
immun
effect
cpg
also
remov
alter
dna
sequenc
replac
cpg
cpg
motif
krieg
et
al
thorough
review
dna
deliveri
technolog
platform
publish
elsewher
nishikawa
huang
yin
et
al
deliveri
dna
encod
gene
interest
power
tool
gene
therapi
import
advanc
toward
goal
made
therapi
approv
fda
thu
far
sever
nonvir
dna
strategi
evalu
clinic
includ
clinic
trial
cancer
therapi
phase
clinic
trial
tumor
suppressor
gene
deliv
lung
cancer
patient
use
dotapcholesterol
liposom
result
transgen
express
activ
apoptot
pathway
lu
et
al
therapi
phase
trial
gene
deliveri
trail
includ
gene
deliveri
np
enhanc
immun
respons
kendrick
et
al
anwer
et
al
codeliveri
two
tumor
suppressor
gene
somatostatin
receptor
subtyp
deoxycytidin
kinas
uridylmonophosph
kinas
dck
umk
complex
pei
buscail
et
al
deliveri
cytotox
diphtheria
toxin
gene
suicid
gene
cancer
specif
promot
pei
np
also
evalu
ovarian
pancreat
bladder
cancer
demonstr
good
safeti
profil
antitumor
efficaci
sidi
et
al
smaldon
davi
hanna
et
al
gofrit
et
al
nonvir
dna
therapeut
show
substanti
efficaci
clinic
trial
pave
way
nonvir
dna
cancer
therapi
diseas
decad
technolog
develop
therapeut
dna
deliveri
human
becom
realiti
goal
mrna
deliveri
dna
deliveri
deliv
therapeut
gene
translat
protein
within
target
cell
contrast
dna
mrna
need
reach
cytosol
recogn
ribosom
transfect
effici
mrna
higher
dna
especi
nondivid
cell
yamamoto
et
al
also
mrna
deliveri
pose
risk
insert
mutagenesi
although
stabil
nake
mrna
poor
chemic
modif
protect
serum
endonucleas
np
deliveri
vehicl
increas
mrna
stabil
dna
exogen
mrna
also
stimul
immun
respons
retino
acid
receptor
respond
protein
rigi
yin
et
al
chemic
modif
reduc
recognit
mrna
immun
system
et
al
structur
mrna
critic
recognit
eukaryot
translat
machineri
core
mrna
structur
open
read
frame
orf
translat
protein
flank
orf
two
untransl
region
utr
end
allow
regul
translat
final
methyl
cap
poli
adenosin
tail
bookend
mrna
necessari
effici
translat
galli
increas
poli
tail
length
also
improv
stabil
holtkamp
et
al
commerci
kit
avail
synthes
mrna
necessari
structur
compon
plasmid
dna
though
optim
target
cell
type
also
help
improv
translat
effici
yamamoto
et
al
dozen
clinic
trial
use
mrna
vaccin
adjuv
express
antigen
either
dendrit
cell
ex
vivo
direct
inject
howev
gene
replac
therapi
still
preclin
develop
kaczmarek
et
al
discov
mirna
class
noncod
regulatori
rna
critic
role
nearli
biolog
process
includ
cancer
mirna
serv
oncogen
tumor
suppressor
farazi
et
al
primari
mirna
transcript
characterist
hairpin
structur
recogn
process
rnase
iii
enzym
drosha
produc
stem
loop
precursor
mirna
premirna
nucleotid
lee
et
al
final
cleavag
dicer
result
matur
dsrna
et
al
matur
nucleotid
mirna
associ
rnainduc
silenc
complex
risc
one
strand
duplex
guid
risc
complementari
sequenc
within
target
mrna
strand
select
risc
like
base
stabil
two
strand
name
correspond
end
mirna
precursor
hairpin
respect
target
sequenc
complimentari
nucleotid
seed
region
mirna
sequenc
frequent
found
utr
mrna
also
within
code
intron
region
bind
mirna
target
mrna
result
degrad
destabil
mrna
also
caus
translat
repress
ha
kim
gener
speak
mirna
target
hundr
uniqu
mrna
thu
regul
transcriptomewid
chang
way
mirna
critic
regul
cell
ident
state
kosik
addit
mirna
essenti
immun
cell
develop
immun
activ
xiao
rajewski
well
crosstalk
cancer
cell
tme
chou
et
al
replac
downregul
mirna
synthet
doublestrand
rna
dsrna
carri
sequenc
endogen
matur
precursor
mirna
use
mirna
mimic
smaller
stabl
mrna
allow
eas
encapsul
sever
type
np
chemic
modif
mirna
made
way
mrna
sirna
increas
stabil
reduc
inflammatori
respons
nucleic
acid
base
inhibitor
mirna
includ
lockednucl
acid
lna
antagomir
antimir
mirspong
character
detail
elsewher
ling
et
al
therapeut
strategi
modul
mirna
function
alreadi
clinic
trial
comprehens
review
mirna
therapeut
provid
elsewher
rupaimool
slack
inhibit
critic
player
hepat
infect
investig
multipl
clinic
trial
inhibit
clinic
trial
alcohol
fatti
liver
diseas
drug
util
unencapsul
antimir
therapeut
target
liver
rel
access
organ
target
nucleic
acid
deliveri
trial
also
progress
cancer
therapi
deliveri
egfrtarget
engen
deliveri
vehicl
nanocel
complet
phase
clinic
trial
mesothelioma
accept
safeti
profil
sign
efficaci
van
zandwijk
et
al
contrast
phase
trial
mimic
multipl
solid
tumor
recent
termin
due
sever
immunerel
marrow
suppress
advers
event
nm
liposom
carrier
compos
ioniz
lipid
use
trial
precis
sourc
inflammatori
due
carrier
mirna
mimic
synergi
known
beg
et
al
rupaimool
slack
clear
go
forward
extens
preclin
evalu
immun
stimul
mirnadirect
therapi
must
import
consider
sirna
nt
dsrna
interact
cytoplasm
risc
complex
degrad
target
mrna
structur
sirna
ident
mirna
modifi
encapsul
way
fact
mirna
mimic
base
endogen
gene
sirna
synthet
design
primari
differ
mirna
sirna
sequenc
specif
instead
mirna
seed
region
nt
complementar
target
mrna
design
sirna
usual
complementar
target
mrna
sirna
potent
activ
singl
target
contrast
mirna
potenti
target
hundr
mrna
gener
inhibit
lesser
extent
target
sirna
degrad
endonucleas
activ
argonaut
associ
risc
mirna
usual
caus
deadenyl
translat
repress
target
mrna
associ
argonaut
complex
devoid
nucleas
activ
therefor
pharmacodynam
mirna
mimic
sirna
import
differ
howev
pharmacokinet
biodistribut
two
oligonucleotid
sinc
chemic
structur
ident
anoth
consider
stimul
immun
respons
exogen
rna
instanc
sirna
within
liposom
polymer
np
induc
inflammatori
cytokin
respons
greater
either
compon
alon
respons
mediat
tlr
sequenc
depend
gurich
sequenc
induc
potent
cytokin
respons
judg
et
al
modif
rna
incorpor
nucleosid
reduc
inflammatori
respons
without
decreas
gene
silenc
judg
et
al
inflammatori
cytokin
respons
observ
sirna
mirna
clinic
trial
therefor
evalu
immunostimul
concern
translat
therapeut
clinic
current
dozen
clinic
trial
sirnabas
therapi
complet
ongo
depth
review
see
wittrup
lieberman
zuckerman
davi
sever
class
noncod
rna
identifi
includ
piwiinteract
rna
endogen
sirna
longnoncod
rna
circular
rna
function
speci
role
diseas
biolog
activ
investig
estel
role
noncod
rna
cancer
biolog
continu
unfold
therapeut
approach
modul
increas
interest
gutschner
diederich
therapeut
deliveri
noncod
rna
face
similar
challeng
type
rna
stabil
uptak
appropri
cell
intracellular
compart
target
manipul
genom
dna
live
cell
possibl
use
engin
nucleas
mega
nucleas
zinc
finger
nucleas
zfn
transcript
activatorlik
effectorbas
nucleas
talen
cluster
regularli
interspac
short
palindrom
repeat
crispr
ca
system
cox
et
al
enthusiasm
surround
genom
edit
technolog
reminisc
gener
discoveri
rnai
fire
et
al
howev
similar
hurdl
imped
therapeut
translat
enact
genom
edit
vivo
nucleas
must
present
within
target
cell
deliveri
protein
may
possibl
approach
util
deliveri
mrna
dna
encod
nucleas
use
viral
vector
aav
deliv
nucleas
rais
addit
concern
integr
nucleas
dna
lead
constitut
express
nucleas
capabl
genom
edit
increas
chanc
offtarget
mutat
reason
transient
express
achiev
np
systemsmay
prefer
highli
specif
gene
edit
tool
rapidli
becom
standard
lab
techniqu
simplest
embodi
requir
presenc
protein
singl
guid
rna
sgrna
present
cell
liu
c
et
al
first
use
clinic
trial
alreadi
taken
place
trial
tcell
exhaust
receptor
genet
remov
ex
vivo
technolog
cell
deliv
patient
cyranoski
similarli
use
remov
receptor
hematopoiet
stem
cell
therapeut
strategi
hiv
sinc
hiv
enter
cell
remov
receptor
expect
reduc
abil
hiv
infect
transplant
cell
li
et
al
applic
techniqu
cellbas
therapi
could
soon
follow
certainli
challeng
edit
cell
vivo
sever
group
work
toward
import
goal
includ
develop
strategi
cancer
treatment
jack
tumorassoci
macrophag
tam
often
protumor
promot
angiogenesi
invas
metastasi
immun
toler
noy
pollard
given
import
role
tumor
progress
grow
interest
target
tam
cancer
therapeut
macrophag
often
character
balanc
pro
antiinflammatori
characterist
macrophag
respect
case
terminolog
oversimplif
use
refer
describ
macrophag
subset
macrophag
character
high
level
major
histocompat
complex
mhc
class
ii
molecul
proinflammatori
cytokin
induc
nitric
oxid
synthas
convers
macrophag
express
low
level
marker
instead
express
high
level
scaveng
receptor
like
mannos
receptor
mr
martinez
et
al
initi
vitro
studi
suggest
macrophag
could
kill
tumor
cell
howev
tme
secret
factor
shift
tam
protumor
phenotyp
sica
et
al
therefor
reprogram
tam
state
could
revers
protumor
effect
review
characterist
np
promot
macrophag
uptak
detail
studi
util
np
gene
deliveri
target
tam
cancer
therapi
np
platform
size
rang
virus
nm
bacteria
consequ
readili
taken
phagocyt
cell
immun
system
macrophag
dendrit
cell
fact
uptak
mononuclear
phagocyt
system
mp
also
call
reticuloendotheli
system
re
consid
critic
obstacl
np
drug
deliveri
one
exampl
first
fda
approv
np
drug
doxil
nanoliposom
formul
doxorubicin
doxil
coat
hydrophil
neutral
polym
peg
reduc
recognit
mp
creat
stealth
effect
work
et
al
despit
modif
clearanc
macrophag
still
major
influenc
doxil
pharmacokinet
labeck
et
al
procliv
macrophag
take
np
even
util
imag
macrophag
vivo
weissled
et
al
interestingli
macrophag
take
nm
peg
hydrogel
np
nm
quantum
dot
higher
rate
macrophag
due
increas
level
scaveng
receptor
mr
suggest
tam
may
especi
sensit
np
deliveri
phenomenon
extend
microparticl
peg
hydrogel
affect
macrophag
polar
jone
et
al
addit
singl
cell
pharmacokinet
np
within
tumor
reveal
tam
serv
reservoir
np
releas
small
molecul
drug
miller
et
al
fate
oligonucleotid
payload
macrophag
less
certain
although
evid
macrophag
may
also
transfer
gene
cell
site
inflamm
haney
et
al
mahajan
et
al
much
effort
gone
reduc
phagocyt
clearanc
np
wealth
studi
detail
characterist
reduc
consequ
enhanc
uptak
popul
detail
review
factor
influenc
macrophag
np
uptak
cover
elsewher
gustafson
et
al
macrophag
np
uptak
occur
micropinocytosi
phagocytosi
receptormedi
endocytosi
gustafson
et
al
factor
influenc
uptak
includ
charg
size
surfac
chemistri
posit
surfac
charg
facilit
uptak
mani
type
cell
neg
membran
potenti
contrast
greater
net
charg
either
posit
neg
direct
increas
uptak
np
macrophag
uptak
chitosan
np
charg
rang
examin
murin
macrophag
cell
increas
charg
neg
posit
direct
increas
macrophag
uptak
nonphagocyt
cell
effici
took
posit
charg
particl
np
size
also
key
determin
larg
np
nm
size
taken
effici
nm
particl
murin
macrophag
et
al
addit
uptak
particl
macrophag
highli
depend
serum
protein
adsorpt
pegyl
decreas
elimin
protein
adsorpt
macrophag
uptak
xie
et
al
walkey
et
al
factor
import
nontarget
passiv
uptak
howev
celltyp
specif
achiev
target
moieti
ligand
antibodi
cell
surfac
receptor
use
decor
np
surfac
enhanc
macrophag
uptak
receptor
mediat
macrophag
np
uptak
includ
folat
receptor
fr
mr
cluster
differenti
legumanin
galactosetyp
ctype
lectin
cluster
differenti
binnemarspostma
et
al
mannos
one
common
macrophag
target
ligand
mr
also
known
also
present
phagocyt
dc
mckenzi
et
al
could
result
offtarget
effect
howev
mr
upregul
tam
decreas
mhc
ii
express
movahedi
et
al
addit
knockout
mice
fewer
tam
reduc
tumor
uptak
mrtarget
nanobodi
indic
mr
bind
deriv
cell
includ
macrophag
movahedi
et
al
mannosyl
polymer
micel
abl
deliv
sirna
mediat
tam
gene
silenc
vitro
vivo
shann
et
al
ortega
et
al
galactosetyp
c
lectin
receptor
also
target
macrophag
nucleic
acid
deliveri
attach
ligand
galactos
surfac
np
huang
et
al
liu
l
et
al
one
sophist
approach
util
dual
target
moieti
apolipoprotein
mimet
serv
ligand
link
macrophag
bind
protein
deliv
npencapsul
sirna
qian
et
al
macrophag
also
express
receptor
capabl
recogn
varieti
pathogenassoci
molecular
pattern
pamp
incorpor
pamp
np
design
facilit
np
uptak
tam
exampl
nanocomplex
incorpor
glucan
pamp
associ
fungi
shown
target
tam
zhang
et
al
b
summari
tam
act
natur
sink
np
target
receptor
specif
ligand
antibodi
facilit
uptak
complet
discrimin
macrophag
mononuclear
cell
clearli
demonstr
small
number
studi
shown
efficaci
nanoparticl
nucleic
acid
deliveri
target
reprogram
tam
cancer
therapi
melanoma
mous
model
deliv
sirna
target
tam
reduc
tumor
growth
prolong
surviv
nontarget
particl
also
inhibit
tumor
growth
dramat
therapeut
effect
correspond
decreas
immunosuppress
cytokin
increas
immunostimmulatori
cytokin
well
increas
function
tcell
qian
et
al
similarli
proinflammatori
deliv
redox
ph
sensit
np
target
galactos
moieti
macrophag
galactosespecif
ctype
lectin
receptor
galactos
target
increas
vitro
uptak
tam
cell
deliveri
np
increas
mhcii
posit
cell
well
decreas
marker
increas
number
activ
tcell
nk
cell
observ
antitumor
effect
elicit
liu
l
et
al
intratumor
inject
modifi
glucan
nanocomplex
carri
sirna
also
shown
effect
inhibit
gene
express
macrophag
deliveri
sirna
migrat
inhibitori
factor
mif
glucan
np
reduc
releas
intracellular
mif
tam
cancer
cell
result
reduc
marker
increas
inflammatori
cytokin
treatment
also
increas
cell
tumor
promot
antitumor
immun
zhang
et
al
b
report
support
oligonucleotid
deliveri
use
reprogram
tam
phenotyp
promot
antitumor
effect
inflammatori
monocyt
im
give
rise
tam
myeloid
suppressor
cell
promot
angiogenesi
subsequ
metastasi
recruit
im
reli
chemokin
qian
et
al
block
axi
receptor
cognat
receptor
subject
clinic
trial
pharmacolog
inhibit
axi
prove
challeng
part
due
rebound
effect
lim
et
al
altern
strategi
use
screen
approach
identifi
optim
lipid
sirna
sequenc
inhibit
monocyt
target
ligand
use
lymphoma
model
inhibit
monocyt
reduc
tumor
size
number
tam
therapi
also
inhibit
express
vegf
reduc
microvessel
densiti
tumor
leuschner
et
al
whether
npbase
target
axi
evad
withdraw
effect
seen
antibodi
target
axi
remain
seen
howev
abil
silenc
gene
monocyt
demonstr
clear
therapeut
potenti
part
innat
immun
respons
pathogen
dendrit
cell
recogn
foreign
materi
pattern
recognit
receptor
prr
compliment
bind
lead
phagocytosi
insid
dendrit
cell
lysosom
process
pathogen
protein
result
gener
peptid
fragment
present
mhc
receptor
recogn
member
adapt
immun
system
cross
present
antigen
dc
tcell
requir
antitumor
immun
dc
primari
target
cancer
vaccin
action
requir
effect
cytotox
tcell
respons
checkpoint
blockad
inhibitor
therapi
np
nm
readili
taken
dendrit
cell
presum
due
size
similar
viral
bacteri
pathogen
size
np
abil
present
multival
antigen
clearli
point
vaccin
applic
bachmann
jen
reason
increas
number
npbase
vaccin
without
addit
immun
agonist
design
cancer
therapi
mizrahi
et
al
consid
addit
incorpor
nucleic
acid
deliveri
smaller
number
studi
util
gene
deliveri
modul
activ
dendrit
cell
subsequ
crosspresent
tcell
surfac
coat
also
increas
dc
np
uptak
exampl
natur
coat
mannosyl
glycosyl
increas
dc
uptak
interact
mr
jiang
et
al
de
coen
et
al
wang
et
al
howev
previous
describ
mr
also
express
macrophag
may
compet
dc
np
uptak
stahl
ezekowitz
altern
antibodybas
target
also
report
one
exampl
clinic
trial
use
target
antibodi
mr
deliv
peptid
antigen
apc
therapi
induc
humor
tcell
respons
melanoma
patient
mors
et
al
report
indic
antibodi
also
enhanc
dc
uptak
increas
downstream
immun
activ
rel
nontarget
np
raghuwanshi
et
al
walter
et
al
use
antibodi
fuse
tumor
antigen
induc
humor
cellular
immun
patient
advanc
malign
dhodapkar
et
al
mr
commonli
use
np
vaccin
target
target
also
test
sehgal
et
al
includ
target
enhanc
uptak
subset
dc
sehgal
et
al
howev
case
materi
composit
np
carrier
may
import
target
ligand
instanc
lipid
base
nanogel
readili
intern
plga
np
look
et
al
also
linear
pei
nanocomplex
effect
antibodytarget
zwitterion
liposom
sirna
deliveri
dc
cubillosruiz
et
al
sever
report
vitro
vivo
shown
deliv
sirna
addit
antigen
peptid
adjuv
dc
enhanc
antitumor
immun
respons
heo
et
al
use
polymer
micel
deliv
tumor
antigen
sirna
immunosuppress
suppressor
cytokin
signal
dendrit
cell
vitro
deliveri
sirna
increas
secret
proinflammatori
cytokin
cultur
dc
activ
tcell
cross
present
heo
et
al
two
addit
studi
heo
et
al
examin
vivo
efficaci
np
sirna
dc
one
studi
investig
formul
multifunct
polymer
np
carri
tumor
model
antigen
ova
dendrit
cell
activ
imiquimod
sirna
immun
activ
induc
inhibit
author
hypothes
combin
would
produc
robust
activ
dc
plga
sirna
np
taken
effici
dc
elicit
cytokin
respons
antigen
crosspresent
traffick
dc
drain
lymph
node
inject
vivo
furthermor
incorpor
sirna
significantli
increas
antitumor
immun
heo
lim
differ
approach
tumor
bear
mice
first
treat
hyaluron
acid
ha
paclitaxel
ptx
complex
induc
immunogen
cell
death
treatment
follow
administr
np
contain
cpg
adjuv
sirna
immunosuppress
cytokin
inhibit
enhanc
immun
respons
multifunct
np
traffick
drain
ln
promot
antitumor
immun
vivo
heo
et
al
ovarian
cancer
tumorassoci
dc
tdc
particularli
tolerogen
role
huart
et
al
inhibit
tolerogen
pathway
dc
sirna
therapeut
benefit
observ
ovarian
cancer
model
addit
sirna
mirna
also
deliv
tdc
induc
antitumor
immun
exampl
deliveri
sirna
member
er
stress
pathway
inhibit
cross
present
tdc
lipid
accumul
np
deliveri
sirna
reduc
metastasi
increas
surviv
ovarian
cancer
model
importantli
phenomenon
ablat
defici
mice
suggest
immun
direct
cancer
target
respons
cubillosruiz
et
al
consid
oncogen
mirna
howev
also
necessari
crosspresent
dc
use
pei
np
deliveri
mimic
produc
potent
antitumor
effect
mice
show
diseas
progress
day
control
succumb
diseas
antitumor
effect
accompani
transcriptom
wide
chang
tdc
highlight
util
mirna
reprogram
tme
cubillosruiz
et
al
interestingli
author
also
found
bulg
dsrna
requir
process
rnase
enzym
dicer
effect
gene
silenc
anoth
aspect
studi
cubillosruiz
et
al
immunestimulatori
effect
pei
np
contain
even
nontarget
rna
tlr
pathway
overal
rna
deliveri
tdc
shown
effect
therapeut
strategi
mous
model
ovarian
cancer
histor
vaccin
reli
peptid
antigen
altern
vaccin
strategi
deliveri
dna
mrna
brief
dna
mrna
encod
antigen
inject
genet
materi
taken
cell
inject
site
translat
protein
protein
encod
dna
mrna
express
myocyt
keratinocyt
inject
site
subsequ
recogn
apc
directli
taken
dc
follow
intern
process
present
dna
vaccin
current
use
veterinari
medicin
thu
far
success
translat
human
rice
et
al
attempt
dna
vaccin
human
reli
nonspecif
target
inject
dna
increas
gene
deliveri
electropor
np
deliveri
system
report
gener
util
cellspecif
target
one
report
plasmid
dna
nucleocapsid
sever
acut
respiratori
syndrom
coronaviru
sarscov
deliv
chitosan
np
target
antibodi
np
dna
deliveri
success
stimul
igg
iga
antibodi
sarscov
nucleocapsid
contrast
nake
dna
produc
detect
antibodi
respons
addit
dc
target
antibodi
significantli
increas
serum
igg
sarscov
nucleocapsid
raghuwanshi
et
al
approach
could
translat
cancer
immunotherapi
well
consider
particl
size
may
critic
induc
cytotox
tcell
ctl
respons
given
dc
necessari
induc
ctl
respons
restrict
lymph
node
therefor
particl
must
drain
lymph
node
requir
particl
size
nm
ideal
bachmann
jen
overal
dc
excit
tme
target
np
nucleic
acid
deliveri
intim
involv
antitumor
respons
requir
action
checkpoint
blockad
therapi
serendipit
phagocyt
abil
prr
also
make
easi
target
np
deliveri
qualiti
gener
increas
interest
npbase
vaccin
like
lead
sever
clinic
trial
multifunct
np
design
deliv
antigen
adjuv
dc
gene
deliveri
strategi
also
consid
within
tumor
stroma
cancerassoci
fibroblast
caf
modul
tumor
growth
metastasi
secret
growth
factor
chemokin
extracellular
compon
kalluri
zeisberg
mani
tumor
especi
desmoplast
tumor
dens
stroma
caf
often
lie
blood
vessel
cancer
cell
make
caf
impedi
cancerdirect
np
deliveri
miao
et
al
cisplatin
np
without
target
larg
taken
caf
desmoplast
pancreat
tumor
miao
et
al
damag
fibroblast
initi
reduc
support
role
promot
tumor
regress
howev
chronic
exposur
induc
express
releas
solubl
factor
resist
chemotherapi
codeliv
sirna
along
cisplatin
np
prevent
resist
pathway
miao
et
al
sinc
find
sever
studi
shown
plasmid
dna
deliv
express
caf
use
lipidbas
np
one
studi
deliveri
gene
produc
solubl
apoptosi
induc
ligand
strail
caf
caus
apoptosi
tumor
parenchyma
ultim
tumor
regress
miao
et
al
similarli
sever
studi
shown
deliveri
pdna
encod
trap
success
deliv
caf
vivo
cancer
therapi
trap
fusion
protein
design
secret
ultim
bound
solubl
factor
tme
chemokin
cytokin
inhibit
factor
metastasi
immunosuppress
shown
reduc
ultim
improv
surviv
anim
model
one
report
trap
combin
trap
promot
tcell
infiltr
reduc
liver
metastasi
pancreat
cancer
either
therapi
alon
miao
et
al
combin
trap
also
decreas
immun
suppress
lymphoid
structur
enhanc
anticanc
vaccin
efficaci
goodwin
et
al
studi
togeth
suggest
caf
use
cellular
factori
product
protein
inhibit
immunosuppress
tme
work
demonstr
possibl
replac
inhibit
endogen
gene
caf
may
feasibl
therapeut
strategi
express
car
primari
tcell
reli
viral
transduct
integr
dna
genom
vitro
manufactur
genet
engin
cell
autolog
transplant
intens
process
rel
low
yield
tcell
resist
mani
form
gene
deliveri
standard
transfect
protocol
effect
current
gene
deliveri
method
tcell
reli
virus
electropor
freeley
long
viral
method
mutagen
electropor
cell
membran
lead
irrevers
cell
damag
low
yield
incorpor
effici
transient
gene
express
np
platform
produc
engin
tcell
hold
promis
improv
immunotherapi
photopor
base
np
one
strategi
approach
transient
permeabil
achiev
ad
gold
np
tcell
follow
short
laser
puls
creat
phototherm
effect
strategi
lower
cytotox
nucleofect
compar
sirnamedi
gene
knockdown
wayteck
et
al
one
potenti
improv
car
tcell
therapi
increas
specif
tcell
mean
remov
noncanc
specif
tcr
toward
aim
moffett
et
al
report
np
deliveri
mrna
tcell
use
antibodi
target
deliveri
megat
nucleas
mediat
elimin
tcell
receptor
alpha
constant
region
trac
effect
remov
abil
tcell
produc
tcr
result
specif
express
car
moffett
et
al
approach
may
forese
reduc
offtarget
immun
respons
test
vivo
anoth
approach
moffett
et
al
increas
proport
central
memori
tcell
critic
cell
popul
establish
effect
immun
respons
enrich
central
memori
tcell
phenotyp
achiev
introduc
encod
mrna
target
np
platform
treatment
tcell
np
increas
activ
carmodifi
tcell
mous
model
bcell
lymphoma
moffett
et
al
report
intrigu
given
preval
viral
method
autolog
tcell
therapi
question
whether
npbase
tcell
gene
deliveri
clinic
translat
despit
greater
clinic
trial
cart
cell
none
current
use
npbase
method
nanoparticlemedi
nucleic
acid
deliveri
tcell
vivo
also
demonstr
np
system
reli
antibodi
surfac
protein
express
tcell
one
instanc
integrin
target
antibodi
use
deliv
lipidbas
np
contain
sirna
leukocyt
system
deliveri
mgkg
mediat
gene
knockdown
peer
et
al
deliveri
sirna
critic
receptor
hiv
entri
lymphocyt
functionassoci
antigen
target
particl
decreas
suscept
human
mice
hiv
infect
kim
et
al
two
studi
subset
leukocyt
target
describ
like
heterogen
consid
target
receptor
present
mani
leukocyt
altern
use
antibodi
decor
lipid
np
specif
deliv
sirna
tcell
vivo
ramishetti
et
al
found
intern
endosom
escap
may
limit
factor
tcell
gene
deliveri
intriguingli
subset
high
low
express
differ
rate
intern
subsequ
gene
silenc
ramishetti
et
al
research
tcell
intern
pathway
character
intern
bind
tcell
specif
receptor
warrant
collect
vivo
deliveri
oligonucleotid
tcell
np
achiev
potenti
therapeut
benefit
cancer
yet
determin
angiogenesi
refer
growth
new
blood
vessel
preexist
vascular
network
healthi
vasculatur
quiescent
due
control
balanc
pro
eg
vegf
fgf
anti
eg
angiostatin
thrombospondin
angiogen
factor
regul
endotheli
cell
prolifer
migrat
jain
tumor
outgrow
local
oxygen
suppli
hijack
regul
perman
shift
balanc
patholog
proangiogen
state
angiogen
switch
folkman
hanahan
folkman
produc
chaotic
dysfunct
vasculatur
normal
blood
vessel
consist
continu
monolay
tightli
adher
ec
close
associ
mural
cell
promot
vessel
stabil
continu
basement
membran
tumor
vessel
loos
associ
ec
larg
gap
poor
mural
cell
recruit
irregular
discontinu
basement
membran
baluk
et
al
reduc
vessel
wall
integr
promot
leaki
cancer
cell
intravas
thu
directli
target
tumor
vessel
either
inhibit
growth
promot
normal
believ
potenti
inhibit
tumor
growth
aggress
well
metastasi
folkman
carmeliet
jain
interestingli
leaki
natur
tumor
blood
vessel
make
challeng
deliv
drug
chemotherapi
tumor
core
also
greatli
facilit
deliveri
np
cancer
cell
due
enhanc
permeabl
retent
effect
prabhakar
et
al
oligonucleotid
deliveri
tumor
endothelium
achiev
multipl
np
platform
gener
success
deliveri
np
vasculatur
confirm
visual
coloc
fluoresc
label
nucleic
acid
packag
np
endotheli
stain
cell
surfac
marker
chitosan
np
demonstr
coloc
tumor
endotheli
cell
vivo
effect
deliv
sirna
cell
type
lu
et
al
orthotop
model
ovarian
carcinoma
treatment
chitosan
np
carri
sirna
target
human
express
transplant
cancer
cell
murin
express
endogen
murin
vasculatur
inhibit
tumor
growth
howev
np
carri
murin
target
sirna
potent
effect
inhibit
diseas
burden
suggest
chitosanmedi
target
tumor
vasculatur
potent
therapeut
effect
target
cancer
cell
directli
lu
et
al
secondgener
np
reli
incorpor
ligand
target
endotheli
cellspecif
surfac
protein
exampl
ligand
integrin
peptid
rgd
use
facilit
np
uptak
neovasculatur
studi
shown
np
contain
chemotherapeut
drug
doxorubicin
direct
specif
tumor
vasculatur
use
ligand
caus
loss
tumor
blood
vessel
decreas
metastasi
murphi
et
al
similarli
deliveri
antimir
inhibit
proangiogen
np
orthotop
xenograft
mous
model
human
breast
cancer
yield
therapeut
effect
inhibit
tumor
vasculatur
decreas
tumor
burden
anand
et
al
mirna
also
deliv
use
rgdlabel
chitosan
np
deliveri
famili
member
use
approach
reduc
angiogenesi
direct
indirect
mechan
result
reduc
diseas
burden
ovarian
cancer
model
pecot
et
al
rgdchitosan
mediat
deliveri
sirna
target
growthpromot
gene
shown
effect
silenc
target
gene
express
endotheli
cell
subsequ
effect
promot
endotheli
apoptosi
inhibit
tumor
growth
heedong
et
al
integrin
also
facilit
uptak
viral
genom
materi
therefor
may
effect
rout
np
base
gene
deliveri
stewart
nemerow
one
report
deliveri
mutant
gene
cation
lipid
np
caus
apoptosi
vessel
surround
tumor
tissu
hood
et
al
anoth
receptor
mediat
uptak
vascular
endothelium
classic
marker
blood
vessel
thought
express
specif
tumor
neovasculatur
well
cancer
cell
type
express
endothelium
blood
lesser
extent
lymphat
use
ligand
deliv
sirna
result
specif
decreas
target
gene
vascular
endothelium
deliv
sirna
tumor
growth
metastasi
inhibit
prostat
cancer
model
santel
et
al
altern
approach
ligandbas
target
chemic
modifi
dendrim
specif
target
endothelium
khan
et
al
np
anoth
type
np
report
local
faith
specif
endothelium
multipl
model
aberr
vascular
function
includ
tumor
angiogenesi
np
abl
elicit
least
knockdown
target
endotheli
gene
express
simultan
deliv
sirna
target
multipl
gene
endothelium
dahlman
et
al
era
clinic
trial
nucleic
acid
deliveri
becom
realiti
expand
scope
consid
new
excit
gene
cell
target
cancer
therapi
np
uptak
cell
within
tme
tradit
consid
deliveri
obstacl
npbase
system
howev
turn
tme
cell
target
could
lead
new
therapeut
strategi
biolog
taught
us
nontransform
cell
act
accessori
cancer
growth
spread
strategi
reprogram
cell
tme
could
result
revolutionari
therapi
studi
highlight
review
demonstr
npbase
nucleic
acid
deliveri
strategi
reprogram
tme
effect
turn
tme
permiss
space
cancer
growth
hostil
one
strategi
synergist
current
immunotherapi
antiangiogen
approach
could
feasibl
extend
efficaci
paradigmshift
treatment
author
list
made
substanti
direct
intellectu
contribut
work
approv
public
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
